Category: MassDevice Q&A
The top three medical device stories for October 17, 2011.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com's coverage highlights our three biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
J. Raymond Elliott left an indelible mark on med-tech goliath Boston Scientific during two years in the corner office. As he passes the torch to interim CEO Hank Kucheman, MassDevice looks back on one of the most boisterous CEOs in the device space.
In two years in the corner office at Boston Scientific Corp. (NYSE:BSX), J. Raymond Elliott left an indelible stamp on the medical device goliath. As he steps down today, handing the keys over to interim CEO Hank Kucheman, he leaves some mighty big shoes to fill.
AccuVein CEO Ron Goldman tells MassDevice about his firm's hand-held vascular imaging technology.
Venipuncture – drawing blood or establishing an intravenous feed – is the most common invasive medical procedure. For many patients, it's a painful exercise in frustration when clinicians struggle to find a blood vessel, sometimes requiring multiple needle sticks.
AccuVein and CEO Ron Goldman aim to change all that with the company's AV300 vascular illumination device. The wireless, handheld module uses a pair of lasers to paint a patient's arm with light, making otherwise invisible or hard-to-find blood vessels apparent to the naked eye.
Stu Randle, CEO of GI Dynamics, discusses the company's recent Australian IPO in an interview with MassDevice.
GI Dynamics (ASX:GID) has been the talk of the medical device industry lately.
Mela Sciences CEO Joseph Gulfo tells MassDevice about the path from nearly assured clearance in June 2009 to the brink of clearance more than two years later.
Click to play
Former Medtronic CEO Bill Hawkins, in an exclusive interview with MassDevice.com, tells us about the one that got away: Guidant Corp.'s stent-making operation.
There's no shortage of ink spilled over the feeding frenzy over Guidant Corp., which ended in Boston Scientific Corp.'s (NYSE:BSX) ill-fated $26 billion acquisition in 2006. But there's one nugget from the spectacle that hasn't received much attention.
Seasoned patent attorney David Dykeman takes us through the America Invents Act in a podcast interview highlighting the challenges and opportunities the reform bill poses for the medical device industry.
This week President Barack Obama is expected to sign a patent reform bill marking the most dramatic changes to the patent system in decades, drawing adulation and ire from varying sectors of the innovation economy.
The American Invents Act, six years in the making, contains several sweeping changes, but the main bone of contention is a transformation of the U.S. patent system from a first-to-invent application process to a first-to-file process.